Albany, NY -- (SBWIRE) -- 04/04/2019 -- Skeletal dysplasia is a rare disease with more than 450 types. It is also widely known as osteochondrodysplasias. It affects the growth and development of the bone and cartilage. The level of severity of this disorder varies from neonatal lethality to growth differences experienced in adulthood. Skeletal dysplasia is difficult to diagnosis, as it is a rare disorder. However, certain symptoms include slow growth, deformities in large head, short upper arms or thighs, curved bones, arthritis or joint pain, and others. The condition is highly prevalent in children and early diagnosis helps creating awareness. This condition is a result of defective genes, which are either inherited from parents or mutated during the development of fetus. The defective gene is extremely difficult to identify. Hence, companies are making significant investments in research & development of treatment for this rare disease.
Read Report Details: https://www.transparencymarketresearch.com/skeletal-dysplasia-market.html
Rise in awareness and early diagnosis of skeletal dysplasia drive the global skeletal dysplasia market. Technological advancements is another factor anticipated to propel the global market in the next few years. Key players are investing in the development of the treatment for this condition. Moreover, prevalence of skeletal dysplasia in children is increasing. These factors are expected to drive the global market. However, less awareness about skeletal dysplasia and poor diagnosis hamper the growth of the global market, especially in developing regions.
According to a journal published on UpToDate, prevalence of skeletal dysplasia is estimated to be 2.4 per 100,000 births globally every day. The prevalence of skeletal dysplasia estimated during pregnancy is 7.5 per 100,000 women screened through ultrasound. It is a rare disease; however, there are 450 different forms of skeletal dysplasia. Patients with this condition undergo extensive medical and surgical treatments throughout childhood and adulthood.
Obtain Report PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=63126
The global skeletal dysplasia market can be segmented based on type, treatment, end-user, and region. In terms of type, the market can be classified into achondroplasia, hypochondroplasia, thanatophoric dysplasia, osteogenesis imperfect, and others. Achondroplasia is the most common type of skeletal dysplasia. According to research, prevalence rate of achondroplasia is 5 in 100,000 and incidence is 1 in 20,000 live births. Based on treatment, the global skeletal dysplasia market can be categorized into medication, surgery, and others. There is no cure for the disorder; however, treatments are recommended for orthopedic and medical conditions caused by skeletal dysplasia. Medications include growth hormones, muscle relaxants, parathyroid hormones, and others. Surgical options include inserting drainage tubes to avoid chronic ear infections, tracheotomy, widening spinal canal process, and correcting physical deformities. In terms of end-user, the market can be divided into hospitals, ambulatory surgical centers, and others.
In terms of region, the global skeletal dysplasia market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018, and the trend is projected to continue during the forecast period. This is due to rise in awareness about the treatment of orthopedic and medical problems, increase in health care expenditure, and presence of key players involved in the clinical trials for development of therapies to cure skeletal dysplasia. Moreover, advanced health care facilities, awareness about early diagnosis, and recognition of orphan drugs by governments boost the growth of the skeletal dysplasia market in the U.S. According to research, the estimated prevalence of this rare bone disease is 1 in 1,600. In Europe, the rare disease affects a small population. It affects 30 million people, of which 6,800 have been identified. The skeletal dysplasia market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Prevalence of rare disorders including skeletal dysplasia, early diagnosis, and prevalence in children are the factors fueling the growth of the market in the region. Expansion of national and international collaborations and technological advancements are expected to augment the skeletal dysplasia market in Asia Pacific.
Ask for the Discount on the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=63126
Currently, there are no therapies for skeletal dysplasia. Major companies involved in the development of therapies in clinical trials include BioMarin Pharmaceuticals, Clementia Pharmaceuticals, Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.
About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.